

Examiner-Initiated Interview Summary	Application No.	Applicant(s)
	10/618,298	YELLIN ET AL.
	Examiner Phillip Gambel	Art Unit 1644
All Participants: (1) <u>Phillip Gambel</u> . (2) <u>James Haley</u> .		Status of Application: _____ (3) _____ (4) _____
Date of Interview: <u>27 March 2007</u>		Time: _____
Type of Interview: <input type="checkbox"/> Telephonic <input type="checkbox"/> Video Conference <input type="checkbox"/> Personal (Copy given to: <input type="checkbox"/> Applicant <input type="checkbox"/> Applicant's representative)		
Exhibit Shown or Demonstrated: <input type="checkbox"/> Yes <input type="checkbox"/> No If Yes, provide a brief description:		
Part I. Rejection(s) discussed:		
Claims discussed: <i>pending</i>		
Prior art documents discussed:		
Part II. SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED: <i>See Continuation Sheet</i>		
Part III. <p> <input checked="" type="checkbox"/> It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability. <input type="checkbox"/> It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above. </p> <div style="text-align: right; margin-top: 10px;">  PHILLIP GAMBEL, PH.D PRIMARY EXAMINER T2 1600 3/27/07 </div>		
(Examiner/SPE Signature)		(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed:

Applicant's election of the species "antibodies (Species A)" and the species "vasculitis (Species H)" in the Reply to Restriction Requirement, filed 1/8/07, was acknowledged.

Upon a review of the instant claims as they read on the elected species, the following was noted.

This application contains claims directed to the following patentably distinct species of the claimed Invention: wherein the "antibody / antibodies" is / are:

- A) CD40-specific antibody / antibodies or
- B) CD40L-specific antibody / antibodies.

During a telephone conversation with James Haley on 03/27/2007, a provisional election was made with traverse to prosecute the species of CD40L-specific antibodies in addition to the species indicated above.